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Summary Fifty-five evaluable patients with disseminated malignant melanoma were treated with the com-
bination of dacarbazine (DTIC) 400 mg i.v. on days 1 to 3 and lomustine (CCNU) 50 to 80 mg m-2 orally on
day 1 with intervals of 6 weeks as the first line chemotherapy. Three (5%) patients had complete and 6 (11%)
partial response, and 7 (13%) patients had stable disease at least for 3 months. The patients with an objective
response (n = 9) survived longer than the rest of the patients if the length of survival was calculated from the
start of chemotherapy (P = 0.0006). However, the responding patients also had longer time interval from the
diagnosis to the detection of distant metastases (P = 0.05), and survival time from disease progression
following DTIC and CCNU therapy (P = 0.005). These findings suggest that patients with an objective
response to DTIC-CCNU therapy have melanoma with a slow progression rate, and prolonged survival in
such patients may in part result from the less aggressive biological nature of their tumours.
Combination chemotherapy has in nonrandomised series
been reported to increase survival of the responding patients
with metastatic melanoma (Seigler et al., 1980), and based on
such results combination chemotherapy has been recom-
mended instead of single-agent therapy despite its greater
toxicity in this uniformly fatal disease (Young et al., 1985).
Subcutaneous, lymph node, and pulmonary melanoma met-
astases respond to chemotherapy more often than visceral or
osseous ones (Joensuu et al., 1986; Mulder et al., 1989;
Thatcher et al., 1989). However, disseminated melanoma
with subcutaneous, lymph node, or pulmonary metastases
may be associated with less aggressive biological behaviour,
and, therefore, the longer survival of the responding patients
might not merely result from a favourable response to
chemotherapy. However, there are currently little data avail-
able in the literature indicating that responding melanoma
metastases have a slower progression rate than those that do
not respond to chemotherapy.
In the present retrospective series of 55 patients treated
with the combination of dacarbazine (DTIC) and lomustine
(CCNU) the progression rate of melanoma was assessed by
calculating the time from the diagnosis to the detection of
distant metastases, and the length of survival after disease
progression following DTIC-CCNU therapy to death, and
these estimates of rate of disease progression were correlated
with response to chemotherapy.
Materials and methods
Sixty patients with histologically diagnosed malignant melan-
oma with distant metastases were treated with DTIC
400 mg i.v. on days 1 to 3 and with CCNU 50-80 mg m-2
p.o. on day 1 with 6 weeks' intervals in the Department of
Radiotherapy and Oncology, Turku University Central Hos-
pital, in 1979 to 1987. Dosage was reduced at some stage of
treatment because of side-effects only in nine cases (in three
responders and in six nonresponders). Fifty-five patients were
evaluable and five nonevaluable for response (two patients
refused to continue therapy after one course, one was lost to
follow-up, in one case metastases were removed by surgery,
and one patient was treated for pulmonary nodules that later
turned out to be probably benign). Thirty were male and 25
female, the mean age was 52 years, range, from 21 years to
72 years. The Karnofsky's status ranged from 50 to 100,
mean 83.
Dissemination of melanoma was confirmed by histology,
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cytology, or by radiography. Nine patients had metastases
confined to subcutaneous tissue or lymph nodes only, 20 had
pulmonary metastases only, 4 liver metastases only, and the
remaining 22 patients had metastases in more than one loca-
tion.
Previous chemotherapy had not been given, but 18 patients
had been irradiated to small local fields, 40 to 60 Gy, and 12
had received adjuvant immunostimulatory treatment after the
diagnosis before starting chemotherapy (three responders and
nine nonresponders to DTIC-CCNU combination). Nineteen
patients were treated with tamoxifen and/or various chemo-
therapy protocols after progression with DTIC and CCNU
(five responders and 14 nonresponders).
Treatment response was assessed according to Miller et al.
(1981). Patients with CR or PR were considered objective
responders. The duration of response was calculated from the
date of occurrence of remission until disease progression.
Survival analyses were done using a BMDP computer
program (BMDP Statistical Software, Department of Bio-
mathematics, University of California Press, Los Angeles,
CA). Survival was estimated with the product-limit method,
and comparison of survival between groups was done with
the generalised Wilcoxon test (BMDP 1L). Frequency tables
were analyzed using Fisher's exact test, and age distributions
were compared with Student's t-test. All P-values are 2-
tailed.
Results
The mean number of cycles given was 4.1 (range, from one
to 18). At writing three patients are alive with disease, and 52
(95%) have died from melanoma. Survival rate 2 years after
starting chemotherapy was 15%, and the median survival
time was 7 months.
The objective response rate was 16% (9/55, 3 CRs, 6 PRs),
and seven patients (13%) had stable disease at least for 3
months. The duration of complete responses were 2, 2, and
18 months, and partial responses 2, 3, 3, 7, 26, and 12 +
months. Objective responses were seen more frequently in
patients with disease confined to subcutaneous tissue or
lymph nodes (4/9, 44%), and in patients with pulmonary
metastases only (4/20, 20%) than in patients with metastases
elsewhere or with multiple involved sites (1/26, 4%, P = 0.03,
Table I). All responders had Karnofsky's status 80 or more,
none of the 11 patients who scored 70 (n = 5), 60 (n = 5) or
50 (n = 1) responded (P = 0.18). The mean age of the pa-
tients with objective response was 60.7 years (SD, 11.1 years),
and that ofthe rest of the patients 50.6 years (SD, 13.9 years,
P = 0.02). Three of the responding patients were male
(P = 0.27).
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Table I Response by site
Location of metastases CR PR SD PD CR + PR/Total
Subcutaneous or nodes only 3 1 2 3 4/ 9 (44%)
Pulmonary only 0 4 4 12 4/20 (20%)
Other visceral/osseous 0 1 1 24 1/26 (4%)
Total 3 (5%) 6 (11%) 7 (13%) 39 (71%) 9/55 (16%)
The patients with an objective response lived significantly
longer than those without (P = 0.0006, Figure Ib). The
median survival time of the responders was 25 months and
that of the nonresponders only 5 months. However, the
responding patients had also longer a time from the diag-
nosis to the detection of distant metastases (P = 0.05, Figure
1a), and survival time from disease progression following
DTIC and CCNU therapy (P = 0.005, Figure lc), which
suggests that patients with an objective response had
melanoma with a slow progression rate. If patients with
stabile disease were combined together with the responding
patients in these survival analyses, the corresponding P
values were P<0.0001 for survival after starting
chemotherapy, P = 0.09 for distant recurrence-free survival,
and P<0.0001 for post-chemotherapy survival.
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Discussion
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In accordance with the present results several authors have
reported that patients with an objective response live a few
months longer than those without a response (Seigler et al.,
1980; Young et al., 1985; York & Foltz, 1988). Hence,
chemotherapy has been thought to prolong survival of the
responding patients (Seigler et al., 1980; Young et al., 1985),
and there has been considered to be little justification for the
choice of nontreatment or even single-agent chemothera-
peutic regimen in advanced melanoma (Young et al., 1985).
However, the possibility of the responding patients to have a
biologically less aggressive disease has not been taken into
account when such treatment policy has been recommended.
Because the responding patients had a longer time interval
from the diagnosis to the appearance of distant metastases, it
is likely that some of the apparent survival benefit shown in
Figure lb resulted from the slower metastatic rate and pos-
sibly from slower growth rate of the tumours of the respon-
ding patients. This hypothesis is supported by the longer time
interval between disease progression after DTIC-CCNU
chemotherapy and death in responding patients as compared
with the nonresponding ones (Figure ic).
DTIC is one of the most active single drugs in metastatic
melanoma with a response rate of 15 to 25% (Comis, 1976;
Legha, 1989). The objective response rate of 16% found in
the present series is similar as we found earlier with 36
evaluable patients (Joensuu et al., 1986), and also not differ-
ent from the response rates obtained with DTIC alone in
metastatic melanoma. Hence, the addition of oral CCNU to
dacarbazine does not appear to be of much clinical value.
Higher response rates up to 40 to 45% have been reported
with 3- or 4-drug regimens, such as BOLD (bleomycin, vin-
cristine, lomustine, and DTIC, Seigler et al., 1980), BELD
(vincristine substituted by vindesine, Young et al., 1985), and
cisplatin, vindesine, and DTIC combination (Pectasides et al.,
1989). However, only five (25%) of the 20 evaluable patients
of Young et al. (1985) and three (11%) of the 27 patients of
Pectasides et al. (1989) had other visceral than pulmonary
metastases, or osseous metastases. Consequently, when the
BOLD regimen has been tested among patients with a larger
proportion of visceral or osseous metastases, the response
rate has dropped from four to 20% (The Prudente Foun-
dation Melanoma Study Group, 1989; York & Foltz, 1988).
The median survival time with BOLD has varied from 4 to 7
months (Seigler et al., 1980; The Prudente Foundation Mel-
anoma Study Group, 1989, Lakhani et al., 1990), which is
not superior to the median surival time of 7 months obtained
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Figure 1 a, Survival of the patients with malignant melanoma
and with an objective response to DTIC-CCNU chemotherapy
(CR/PR, n = 9), and the patients without an objective response
(SD/PD, n = 42) as calculated from the data of the diagnosis to
the date of detection of distant metastases. In four cases the date
of excision of the primary tumour was not known with certainty
or the primary tumour was not found. b, Survival as calculated
from the start of chemotherapy to death (n = 52) or the last day
of follow-up (n = 3). In CR/PR n =9, in SD/PD n = 46. c,
Survival as calculated from the date of disease progression fol-
lowing DTIC-CCNU chemotherapy to death or the last date of
follow-up. In CR/PR n = 8 (1 patient has not had disease pro-
gression, in SD/PD n = 46.
in the present series, but the toxicity of the 4-drug regimen
appears to be greater (York & Foltz, 1988).
There is currently no solid evidence that chemotherapy
prolongs survival in disseminated melanoma, even if given as
adjuvant therapy. Interferons and interleukin-2 induce tu-
mour regression in 15 to 20% of patients, but are associated
with considerable side effects (Legha, 1989). Currently, the
results of chemotherapy in the treatment of disseminated
malignant melanoma continue to be mostly disappointing
(Ahman et al., 1989). High dose chemotherapy with auto-
logous bone marrow rescue has produced impressive res-
ponse rates up to 81% with a 25% complete response rate,
but the median survival value remained as 6 months with no
survival benefit (Thatcher et al., 1989; Lakhani et al., 1990).
The present results indicate that prolonged survival of
patients responding to chemotherapy as compared to those
not responding to it may be poor evidence for survival
benefit produced by chemotherapy. Responding tumou156 H. JOENSUU
may have different inherent biological characteristics from
the nonresponding tumours, and the alleged survival benefits
based on chemotherapy response have also been criticised
from a statistical point of view (Anderson et al., 1983).
Treatment recommendations based on such evidence should
be viewed with suspicion, because treatment with toxic multi-
drug combinations may lead to increased costs and undue
iatrogenic suffering for these fatally ill patients.
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